The company will analyze samples from the University for protein biomarkers.

Power3 Medical Products will work with the University of Thessaly in Larissa, Greece, with a focus on the proteomic discovery of biomarkers for Parkinson’s disease.

The University of Thessaly will provide Power3 with clinically confirmed samples of neurodegenerative disease, including age- and gender-match controls. Power3 will analyze the samples for new protein biomarkers for the early detection of neurodegenerative diseases to add to its portfolio.

The collaboration will also extend to cover other neurodegenerative diseases, including Alzheimer’s disease and ALS.

Previous articleNDRI Receives Funding Commitment for Rare Disease Initiative
Next articleSemafore Receives Nearly $1M to Put First PI3K Inhibitor into Trial